Orion Oyj Class A · OMXHEX:ORNAV
Orion Oyj Class A — Investor Day (May 2025)
8 slides from Orion Oyj Class A's investor day presentation, May 21, 2025
Slide 1: Animal Health
Animal Health Niclas Lindstedt Executive Vice President 1
Slide 2: Orion Pharma Animal Health today
Orion Pharma Animal Health today The road is open for growth after some eventful years We develop, in-license, manufacture and 2021: Loss of significant distribution agreement (~MEUR 28) market innovative and generic drugs for 2022: Acquisition of Inovet (VMD) 2023: Headwinds from partner de-stockin
Slide 3: Animal Health sales worldwide
Animal Health sales worldwide Captive markets Partner markets
Slide 4: Animal Health market review
Animal Health market review Market split in 2023 Market trends 96.56 +5.13% • No. of pets increasing (North America & Europe) • Population growth means 61.56 39% increased food production (Asia, Africa, South America) 61% • Customer base is consolidating • Technology, AI/data usage and investments a
Slide 5: Focus areas of Animal Health R&D
Focus areas of Animal Health R&D • New therapeutic modalities Reduction, Replacement and Refinement • Selected target species and indications (3Rs) of antibiotics • Sustainable use of antibiotics • Pet care products • New therapeutic modalities • Selected target species and indications Anesthesia an
Slide 6: How Animal Health is building growth
How Animal Health is building growth Growth through innovation Growth through market growth • Internal innovative R&D – main focus • Expected market growth CAGR on companion animals 5.13% until 2033 • Generic development – mainly for • Leverage wide networks and good livestock customer relationships
Slide 7: Our purpose
OUR PURPOSE “Our mission is to provide meaningful, compassionate animal health care that prioritizes the well-being of animals and their caregivers.”
Slide 8: Q&A
Q&A GRION PHARMA ANIMAL HEALTH PHARMA